| Dermatitis, Atopic
Cibinqo vs Zoryve Cream
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Cibinqo vs Zoryve with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZoryve has a higher rate of injection site reactions vs Cibinqo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zoryve but not Cibinqo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cibinqo
Zoryve
At A Glance
Oral
Once daily
JAK inhibitor
Topical
Daily
PDE4 inhibitor
Indications
- Dermatitis, Atopic
- Psoriasis vulgaris
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic 100 mg orally once daily; may increase to 200 mg once daily for inadequate response. In moderate renal impairment or CYP2C19 poor metabolizers: 50 mg once daily, may increase to 100 mg once daily for inadequate response.
Psoriasis vulgaris Apply ZORYVE cream, 0.3%, to affected areas once daily in adult and pediatric patients 6 years of age and older.
Dermatitis, Atopic Apply ZORYVE cream, 0.15%, once daily for patients 6 years of age and older; apply ZORYVE cream, 0.05%, once daily for pediatric patients 2 to 5 years of age.
Contraindications
- Patients taking antiplatelet therapies (except low-dose aspirin <=81 mg daily) during the first 3 months of treatment
- Moderate to severe liver impairment (Child-Pugh B or C)
Adverse Reactions
Most common (>=1%) Nasopharyngitis (8.7-12.4%), nausea (6.0-14.5%), headache (6.0-7.8%), herpes simplex (3.3-4.2%), increased blood creatine phosphokinase (2.3-2.9%), dizziness (1.8-2.9%), urinary tract infection (1.7-2.2%), fatigue (1.3-1.6%), acne (1.6-4.7%), vomiting (1.5-3.2%), impetigo (0.5-1.5%), oropharyngeal pain (1.0-1.4%), hypertension (0.8-1.2%), influenza (1.1-1.2%), gastroenteritis (1.1-1.3%), dermatitis contact (0.5-1.1%), abdominal pain upper (0.6-1.9%), abdominal discomfort (0.5-1.2%), herpes zoster (0.3-1.2%), thrombocytopenia (0-1.5%)
Serious Serious infections including herpes simplex, herpes zoster, and pneumonia (2.3 per 100 patient-years); thrombosis including pulmonary embolism and deep vein thrombosis; major adverse cardiovascular events; malignancy; retinal detachment
Most common (>=1%), Plaque Psoriasis Diarrhea, headache, insomnia, nausea, application site pain, upper respiratory tract infection, urinary tract infection
Most common (>=1%), Atopic Dermatitis Headache, nausea, application site pain, diarrhea, vomiting, upper respiratory tract infection, rhinitis, conjunctivitis
Pharmacology
Abrocitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits JAK1 by blocking the ATP binding site. It is selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and TYK2 (43-fold).
PDE4 inhibitor; roflumilast and its active metabolite (roflumilast N-oxide) inhibit PDE4, a major cyclic AMP-metabolizing enzyme, leading to accumulation of intracellular cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cibinqo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Zoryve
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Cibinqo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Zoryve
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Cibinqo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Zoryve
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Arcutis Cares Patient Assistance: ZoryveCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CibinqoView full Cibinqo profile
ZoryveView full Zoryve profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.